Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Xiao-Feng Powder (mXFP) is a traditional Chinese medicine (TCM) herbal formula that has been widely used for the treatment of chronic urticaria and other allergic skin diseases. It is typically composed of multiple herbs designed to "expel wind," "clear heat," nourish blood, and relieve itching according to TCM theory[1][2][4]. The combination with antiallergic drugs—primarily modern antihistamines such as cetirizine, loratadine, mizolastine, ebastine, or chlorpheniramine—aims to enhance therapeutic efficacy by integrating TCM with Western pharmacotherapy[5]. Clinical studies suggest that this combination may provide superior symptom control and lower recurrence rates compared to antihistamines alone in chronic urticaria patients[2][4][5]. The mechanism of action involves both the immunomodulatory effects attributed to the herbal components (such as anti-inflammatory activity and modulation of immune responses) and the well-established histamine H1 receptor antagonism provided by conventional antiallergic agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified xiao-feng powder + antiallergics.